## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION

RECEIVED USEC, CLEEK CHARLES FOR ANY, S
--

	7015 JUL 20 P 12: 19
	)
IN RE: LIPITOR (ATORVASTATIN	) MDL No. 2:14-mn-02502-RMG
CALCIUM) MARKETING, SALES	)
PRACTICES AND PRODUCTS	) CASE MANAGEMENT ORDER NO. 37
LIABILITY LITIGATION	)
	) This Document Relates to:
	) 2:14-cy-3995-RMG
	)
	)
	<i>)</i>

## ORDER APPROVING JOINT STIPULATION

In light of the Joint Stipulation re Defendant Pfizer Inc.'s ("Pfizer") Motion to Dismiss Plaintiffs' Cases for Failure to Comply with Discovery Obligations ("Stipulation"), (Dkt. No. 946), and for good cause shown, it is hereby ORDERED, with respect to the Plaintiffs in Maggy Garabedian, et al. v. Pfizer Inc., et al., case number 2:14-cv-03995-RMG ("Garabedian Plaintiffs"), that:

- 1. The Garabedian Plaintiffs' time to provide compliant Plaintiffs Fact Sheets ("PFS") and other mandatory disclosures is extended to August 24, 2015;
- The Garabedian Plaintiffs' time to respond to Pfizer's Motion to Dismiss (DKt. No. 934) is extended to August 25, 2015;
- 3. With respect to the *Garabedian* Plaintiffs who provide compliant PFSs and other mandatory disclosures by August 24, 2015, Pfizer's Motion to Dismiss will be withdrawn without prejudice to Pfizer's rights set forth in paragraph 8 below;

2:14-mn-02502-RMG Date Filed 07/20/15 Entry Number 949 Page 2 of 2

With respect to the Garabedian Plaintiffs who fail to provide their PFSs and other

mandatory disclosures by August 24, 2015, and who do not voluntarily dismiss

their actions pursuant to paragraph 7 by August 24, 2015, Pfizer's Motion to

Dismiss will proceed as to those plaintiffs as of August 25, 2015;

5. With respect to individual Plaintiff Doris Rowland, Pfizer's Motion to Dismiss is

withdrawn;

4.

6. The Garabedian Plaintiffs will not seek or move for remand of their actions to

California state court;

7. To the extent any of the Garabedian Plaintiffs seek a voluntary dismissal of their

claims, he or she will agree to all the terms of dismissal required by the Court in

CMO 12, including an agreement that any re-filing of the action will be in federal

court; and

8. Pfizer shall retain the right to identify any deficiencies in the PFSs or disclosures

provided by the Garabedian Plaintiffs and shall retain the right to make an

appropriate motion if such deficiencies are not timely cured.

AND IT IS SO ORDERED.

Richard Mark Gergel

United States District Court Judge

July 2015 Charleston, South Carolina

2